S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

NCT00087412 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Lung
Large Cell Lung Cancer
Recurrent Non-small Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)